Compare EPM & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EPM | ORGO |
|---|---|---|
| Founded | 2003 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.7M | 127.6M |
| IPO Year | 1996 | 2016 |
| Metric | EPM | ORGO |
|---|---|---|
| Price | $3.49 | $0.99 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 2 |
| Target Price | ★ $4.88 | $2.00 |
| AVG Volume (30 Days) | 362.1K | ★ 1.2M |
| Earning Date | 11-10-2026 | 11-05-2026 |
| Dividend Yield | ★ 13.83% | N/A |
| EPS Growth | N/A | ★ 1600.00 |
| EPS | ★ N/A | N/A |
| Revenue | $43,229,621.00 | ★ $564,169,000.00 |
| Revenue This Year | $6.78 | N/A |
| Revenue Next Year | N/A | $37.55 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 17.04 |
| 52 Week Low | $3.19 | $0.73 |
| 52 Week High | $4.99 | $6.20 |
| Indicator | EPM | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 40.34 | 47.33 |
| Support Level | $3.40 | $0.93 |
| Resistance Level | $3.85 | $2.58 |
| Average True Range (ATR) | 0.15 | 0.10 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 33.41 | 74.39 |
Evolution Petroleum Corp is an independent energy company focused on owning and investing in onshore oil and natural gas properties across the United States. Its portfolio includes non-operated interests in various production fields such as CO2 enhanced oil recovery in Louisiana, secondary recovery production in Wyoming, and shale gas reservoirs in Texas and North Dakota. The company generates revenue from the production and sale of oil and natural gas, leveraging specialized technologies to extend reservoir life and enhance recoveries.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.